Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice

Angela Lamarca, Melissa Frizziero, Jorge Barriuso, Mairead Mcnamara, Richard A Hubner, Juan W Valle

Research output: Contribution to conferenceAbstractpeer-review


Introduction: Platinum-etoposide chemotherapy is a globally established chemotherapy combination for EP-G3-NEC. However, there are many different schedules for such chemotherapy, and the preferred one for EP-G3-NEC has not been established. Methods: An international survey was created, and completed by colleagues with an expertise in the field of neuroendocrine neoplasms. The aim was to explore which schedules of platinum-etoposide chemotherapy are used across centres and to assess consistency in clinical practice. Results: Sixty four replies were received (June-August’17); completed by medical oncologists (43;67.2%), clinical oncologists (11;17.2%), gastroenterologists (8;12.5%) and endocrinologists (2;3.1%). United Kingdom was the most represented country (25;39.1%), followed by Spain (13;20.3%). Most of the physicians completing the survey (39;60.9%) had >10 years of experience in the field; 29 (46.0%) were working in European Neuroendocrine Tumor Society (ENETS) Centres of Excellence (CoE). A small minority did not take Ki67 (7;11.1%) or morphology (7;10.9%) into consideration when selecting type of chemotherapy to be administered. Regarding choice of chemotherapy, most (61;95.3%) agreed on selecting platinum-etoposide chemotherapy as first-line treatment for NEC tumours ± poor-differentiation ± Ki67>55%, although there was a large number of different schedules used: cisplatin-based (28/60;46.7%), carboplatin-based (32/60;53.3%). Most centres chose a schedule with intravenous etoposide (53/60;88.3%), while oral etoposide was less popular (7/60;11.7%). Chemotherapy was usually administered up to a maximum of 6 cycles (49;79.0%). At time of progression, choice of second-line chemotherapy was influenced by the time between completion of first-line chemotherapy and tumour progression. When this period was >6 months, re-challenge with platinum-etoposide was the preferred choice (29;46.0%). Conversely, when time to progression was <6 months, platinum-etoposide was not considered by any of the physicians as an option for second-line chemotherapy (0%), and alternative combinations such as fluoropyrimidine/irinotecan (21;34.4%) and temozolomide/capecitabine (18; 29.5%) were preferred. Conclusions: Although there appears to be consensus in selection of platinum-etoposide based chemotherapy for first-line treatment for patients with advanced EP-G3-NEC, significant variation in the exact regimen employed across different institutions exists. Prospective studies in this patient population are required in order to standardise practice.
Original languageEnglish
Publication statusPublished - Dec 2017
EventUKI NETS 2017 - London
Duration: 4 Dec 2017 → …


ConferenceUKI NETS 2017
Period4/12/17 → …


  • Platinum
  • Etoposide
  • Survey
  • neuroendocrine carcinoma


Dive into the research topics of 'Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice'. Together they form a unique fingerprint.

Cite this